Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced mela-noma remains challenging due to frequent treatment resistance. Resistance may be intrin-sic (primary) or emerge after an initial response (secondary). Biomarkers predicting distinct resistance phenotypes befo...
ORGANISM(S): Homo sapiens (Human)